- Home
- TOYO vs CLLS Comparison
TOYO vs CLLS Comparison
Compare TOYO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- CLLS
- Stock Information
- Founded
- TOYO 2022
- CLLS 1999
- Country
- TOYO Japan
- CLLS France
- Employees
- TOYO N/A
- CLLS N/A
- Industry
- TOYO
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- TOYO
- CLLS Health Care
- Exchange
- TOYO NYSE
- CLLS Nasdaq
- Market Cap
- TOYO 153.8M
- CLLS 143.4M
- IPO Year
- TOYO N/A
- CLLS 2007
- Fundamental
- Price
- TOYO $3.69
- CLLS $1.58
- Analyst Decision
- TOYO
- CLLS Buy
- Analyst Count
- TOYO 0
- CLLS 1
- Target Price
- TOYO N/A
- CLLS $4.00
- AVG Volume (30 Days)
- TOYO 12.5K
- CLLS 54.7K
- Earning Date
- TOYO 08-21-2025
- CLLS 08-05-2025
- Dividend Yield
- TOYO N/A
- CLLS N/A
- EPS Growth
- TOYO 350.49
- CLLS N/A
- EPS
- TOYO 1.09
- CLLS N/A
- Revenue
- TOYO $176,957,128.00
- CLLS $54,747,000.00
- Revenue This Year
- TOYO N/A
- CLLS $48.52
- Revenue Next Year
- TOYO N/A
- CLLS $5.17
- P/E Ratio
- TOYO $3.40
- CLLS N/A
- Revenue Growth
- TOYO 183.69
- CLLS 351.26
- 52 Week Low
- TOYO $1.36
- CLLS $1.10
- 52 Week High
- TOYO $7.22
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- CLLS 64.58
- Support Level
- TOYO N/A
- CLLS $1.41
- Resistance Level
- TOYO N/A
- CLLS $1.65
- Average True Range (ATR)
- TOYO 0.00
- CLLS 0.10
- MACD
- TOYO 0.00
- CLLS 0.03
- Stochastic Oscillator
- TOYO 0.00
- CLLS 93.81
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries, is engaged in research and development, production, and sales of solar cells. Geographically, the company generates revenue from Asia and the USA, out of which the majority of revenue is generated from Asia.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.